Loss and restoration of immune privilege in eyes with corneal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 37, Issue 12, 1996, Pages 2485-2494

  Dana, M Reza ^a   Streilein, J Wayne ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

angiogenesis; anterior chamber associated immune deviation; corneal neovascularization; corticosteroids; immune privilege

Indexed keywords

DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISOLONE ACETATE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG MECHANISM; IMMUNOREACTIVITY; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ANIMALS; ANTERIOR CHAMBER; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CORNEA; CORNEAL NEOVASCULARIZATION; DICLOFENAC; HYPERSENSITIVITY, DELAYED; IMMUNE SYSTEM; MICE; MICE, INBRED BALB C; OVALBUMIN; PREDNISOLONE; TETRAHYDROCORTISOL;

EID: 0029802472     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Klintworth GK, Burger PC. Neovascularization of the cornea: Current concepts of its pathogenesis. Int Ophthalmol Clin. 1983;23:27-39.
2. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis and inhibition. Cornea. 1987;6:250-257.
3. Conn H, Berman M, Kenyon K, Langer R, Gage J. Stromal vascularization prevents corneal ulceration. Invest Ophthalmol Vis Sci. 1980;19:362-370.
4. Ey RC, Hughes WF, Bloome MA, Tallman CB. Prevention of corneal vascularization. Am J Ophthalmol. 1968;66:1118-1131.
5. Khodadoust AA. The allograft rejection reaction: The leading cause of late failure of clinical corneal grafts. Ciba Found Symp. 1973;15:151-167.
6. Alldredge OC, Krachmer JH. Clinical types of corneal transplantation rejection. Arch Ophthalmol. 1981; 99:559-604.
7. The Collaborative Corneal Transplantation Studies Research Group. The Collaborative Corneal Transplantation Studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110:1392-1403.
8. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies. Ophthalmology. 1994;101:1536-1547.
9. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea. 1995;14:604-609.
10. Dana MR, Goren MB, Gomes JAP, Laibson PR, Rapuano CJ, Cohen EJ. Suture erosion after penetrating keratoplasty. Cornea. 1995;14:243-248.
11. Mader TH, Stulting RD. The high-risk penetrating keratoplasty. Ophthalmol Clin North Am. 1991;4:411-426.
12. Bishop VLM, Robinson LP, Wechsler AW, Billson FA. Corneal graft survival: A retrospective Australian study. Aust N Z J Ophthalmol. 1986;14:133-138.
13. Volker-Dieben HJ, D'Amaro J, Kok-Van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol. 1987;15:11-18.
14. Niederkorn JY. Immune privilege and immune regulation in the eye. Adv Immunol. 1990;48:191-226.
15. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Report from the Australian corneal graft registry. Ophthalmology. 1992;99:403-414.
16. Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye. 1995;9:236-240.
17. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber associated immune deviation induction. I. Delayed hypersensitivity to donor antigens. Invest Ophthalmol Vis Sci. 1995;36:2176-2185.
18. Streilein JW. Immune regulation and the eye: A dangerous compromise. FASEB J. 1987;1:199-208.
19. Niederkorn J, Streilein JW, Shadduck JA. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci. 1980;20:355-363.
20. Streilein JW. Anterior chamber associated immune deviation: The privilege of immunity in the eye. Surv Ophthalmol. 1990;35:67-73.
21. Streilein JW, Wilbanks GA, Cousins SW. Immunoregulatory mechanisms of the eye. J Neuroimmunol. 1992;39:185-200.
22. Cousins S, Trattler W, Streilein JW. Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye. Curr Eye Res. 1991; 10:287-297.
23. Streilein JW, Bradley D, Sano Y, Sonoda Y. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci. 1996;37:413-424.
24. Li WW, Casey R, Gonzalez EM, Folkman J. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci. 1991;32:2898-2905.
25. Haynes WL, Proia AD, Klintworth GK. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci. 1989;30:1588-1593.
26. Kosiewicz MM, Okamoto S, Miki S, Ksander BR, Shimizu T, Streilein JW. Imposing deviant immunity on the presensitized state. J Immunol. 1994;153:2962-2973.
27. Jager MJ, Gregerson DS, Streilein JW. Regulators of immunological responses in the cornea and the anterior chamber of the eye. Eye. 1995;9:241-246.
28. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
29. Knisely TL, Hosoi J, Nazareno R, Granstein R. Aqueous humor-contains biologically significant concentrations of glucocorticoids but little or no cortisol binding globulin: Relevance to immune privilege in the anterior chamber of the eye. Invest Ophthalmol Vis Sci. 1994;35:3711-3723.
30. Niederkorn JY, Peeler JS, Ross J, Callanan D. The immunogenic privilege of corneal allografts. Reg Immunol. 1989;2:117-124.
31. Collin HB. Ultrastructure of lymphatic vessels in the vascularized rabbit cornea. Exp Eye Res. 1970;10:207-213.
32. Smolin G, Hyndiuk RA. Lymphatic drainage from vascularized rabbit cornea. Am J Ophthalmol. 1971;72:147-151.
33. Eliason JA. Leukocytes and experimental corneal vascularization. Invest Ophthalmol Vis Sci. 1978;17:1087-1095.
34. Fromer GH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. III. Studies related to the vasoproliferative capability of polymorphonuclear leukocytes and lymphocytes. Am J Pathol. 1976;82:157-166.
35. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. New Engl J Med. 1993;328:106-113.
36. Belsito DV, Flotte TJ, Lim HW, Baer RL, Thorbecke GJ, Gigli I. Effect of glucocorticoids on epidermal Langerhans cells. J Exp Med. 1982;155:291-302.
37. Belsito DV, Baer RL, Thorbecke GJ, Gigli I. Effect of glucocorticoids and gamma radiation on epidermal Langerhans cells. J Invest Dermatol. 1984;82:136-138.
38. Sullivan S, Bergstresser PR, Tigelaar RE, Streilein JW. Induction and regulation of contact hypersensitivity by resident, bone-marrow, dendritic epidermal cells: Langerhans cells and Thy-1 + epidermal cells. J Immunol. 1986;137:2460-2467.